Social Protection Policy Analysis, Tanzania
A 2013 Plan study across 30 countries found that children with disabilities were on average 10 times less likely to go to school than children without disabilities. This report presents the findings of a follow-up second phase to the research with a qualitative study on barriers and enablers to educ...ation for children with disabilities in Nepal.
The Full Report and Executive Summary Reports in English, French and Spanish are now available for download at:
http://disabilitycentre.lshtm.ac.uk/include-us-education-study-available-now/
more
You can download different versions (mp4 or mov)
Analysis of survey data looking at 25 years of progress in and the future challenges for tropical medicine and global health
Funded by CBM: www.cbm.org
This two-week free course looks at the science behind the Ebola outbreak, to understand why it has occurred on this scale and how it can be controlled
- See more at: http://www.lshtm.ac.uk/study/freeonlinecourses/ebola/index.html#sthash.77ztaO8A.dpuf
Start: 19 January 2015
Duration: 2 weeks,6 hou...rs per week
Email inquiries: sutdy@lshtm.ac.uk
more
This tracker, developed by the Vaccine Centre at the London School of Hygiene & Tropical Medicine, will follow COVID-19 vaccine candidates as they progress through the development pipeline. We will update it weekly. An overview of the different vaccine types as well as the phases of clinical develo...pment is provided in the Summary tab.
more
Schistosomiasis, which is the second most important parasitic infection after malaria in terms of its socioeconomic impact, is responsible for the loss of an estimated 4.5 million disability-adjusted life years (DALYs) worldwide. Schistosomiasis, including both intestinal and urinary forms of the di...sease, occurs in 78 countries across the globe. An estimated 240 million people are infected, with more than 779 million living at risk globally. The majority of those infected and those at risk for infection live in low-income countries, and approximately 80% of the morbidity occurs in impoverished communities and households in sub-Saharan Africa. Within Uganda, 91 of the 134 districts are endemic for intestinal schistosomiasis caused by Schistosoma mansoni, and the eastern region, especially along Lake Victoria, has one of the highest S. mansoni burdens worldwide. Schistosoma haematobium is only endemic in the five districts of the Lango region in northern Uganda.
more
Yaws is a chronic tropical skin disease that mainly affects children in remote, tropical and often impoverished areas. The disease presents with highly infectious lesions of the skin which can spread to the cartilage and bone. It is one of three endemic treponenatoses and is caused by the spirochete... bacteria Treponema pallidum subsp. pertenue. Under the proposed World Health Organization’s new NTD Roadmap 2030, yaws has been targeted for global eradication by 2030.
more
Infections by the soil-transmitted helminths (STH), including Ascaris lumbricoides, Trichuris trichiura, Ancylostoma duodenale/Necator americanus (hookworms), and Strongyloides stercoralis, disproportionately affect children around the world. Because of their transmission associated with poor sanita...ry conditions and inadequate hygiene practices, higher burden of disease is seen in children from developing countries from sub-Saharan Africa, Southeast Asia, and Latin America. Approximately 267 million preschool-age children (PSAC) and 568 million school-age children (SAC) worldwide are at risk of STH infection as well as impaired child growth and cognitive development from A. lumbricoides, T. trichiura, and hookworm infections, and death due to severe S. stercoralis infection. Thus, their control is a global health priority.
more
To eliminate lymphatic filariasis (LF) by 2020, the World Health Organization (WHO) has launched a campaign against the disease. Since the launch in 2000, significant progress has been made to achieve this ambitious goal. In this article we review the progress and status of the LF programme in Afric...a through the WHO neglected
tropical diseases preventive chemotherapy databank, the Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN) portal and other publications. In the African Region there are 35 countries endemic for LF. The Gambia was reclassified as not requiring preventive chemotherapy in 2015, while Togo and Malawi eliminated LF as a public health problem in 2017 and 2020, respectively. Cameroon discontinued mass drug administration (MDA) and transitioned to post-MDA surveillance to validate elimination. The trajectory of coverage continues to accelerate; treatment coverage increased from 0.1% in 2000 to 62.1% in 2018. Geographical coverage has also significantly increased, from 62.7% in 2015 to 78.5% in 2018. In 2019, 23 of 31 countries requiring MDA achieved 100% geographic coverage. Although much remains to be done, morbidity management and disability prevention services have steadily increased in recent years. Vector control interventions conducted by other programmes, particularly malaria vector control, have had a profound effect in stopping transmission in some endemic countries in the region. In conclusion, significant progress has been made in the LF programme
in the region while we identify the key remaining challenges in achieving an Africa free of LF.
more
Mapping is a prerequisite for effective implementation of interventions against neglected tropical diseases (NTDs). Before the accelerated World Health Organization (WHO)/Regional Office for Africa (AFRO) NTD Mapping Project was initiated in 2014, mapping efforts in many countries were frequently ca...rried out in an ad hoc and nonstandardized fashion. In 2013, there were at least 2,200 different districts (of the 4,851 districts in the WHO African region) that still required mapping, and in many of these districts, more than one disease needed to be mapped. During its 3-year duration from January 2014 through the end of 2016, the project carried out mapping surveysfor one ormore NTDs in at least 2,500 districts in 37 African countries. At the end of 2016, most (90%) of the 4,851 districts had completed the WHO-required mapping surveys for the five targeted Preventive Chemotherapy (PC)-NTDs, and the impact of this accelerated WHO/AFRO NTD Mapping Project proved to be much greater than just the detailed mapping results themselves. Indeed, the AFRO Mapping
Project dramatically energized and empowered national NTD programs, attracted donor support for expanding these programs, and developed both a robust NTD mapping database and data portal. By clarifying the prevalence and burden
of NTDs, the project provided not only the metrics and technical framework for guiding and tracking program implementation and success but also the research opportunities for developing improved diagnostic and epidemiologic sampling tools for all 5 PC-NTDs—lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiasis, and trachoma.
more
Lymphatic filariasis (LF) is a parasitic disease that is a major cause of chronic disability in the developing world. According to the 2021–2030 road map for neglected tropical diseases (NTDs) published by the World Health Organization (WHO), the global goal for LF is elimination as a public healt...h problem by 2030 through repeated rounds of mass drug administration (MDA). Critical components of any elimination program are monitoring and surveillance. Appropriate assessment tools and methods are needed for each stage of an elimination program; mapping to identify which areas require intervention, monitoring to assess the impact of interventions, and post-intervention surveillance to validate elimination or detect recrudescence.
more
Schistosomiasis and soil-transmitted helminths (STH) infections are major public health problems. We aimed to study the 6-mo impact of mass drug administration with praziquantel and albendazole on urinary schistosomiasis and STH.We examined children (aged 2–15 y) from one hamlet, who provided urin...e and faeces samples at baseline (n=197), 1 mo (n=102) and 6 mo (n=92); 67 completed the protocol.At baseline, 47/67 (70.1%) children presented Schistosoma haematobium (75.8% in the baseline total sample) and 12/67 (17.9%) with STH (30.5% in the initial sample, p=0.010). Among the children, 47.3% had heavy Schistosoma haematobium infection. The most frequent STH was Trichuris trichiura in 9.0%. We also found Hymenolepis nana (13.2%) and Plasmodium falciparum (9.1%) infections and anaemia (82.1%). One mo after chemotherapy there was a significant (p=0.013) reduction of Schistosoma haematobium prevalence (23.5%) and a high egg reduction rate (86.9%). Considering the sample of 67 children, the mean egg concentration was 498 at baseline, 65 at 1 mo and 252 at 6 mo (p<0.05). We also observed a reduction in STH infections, 50% in Ascaris lumbricoides, 33.3% in T. trichiura and 50% in hookworms. At 6 mo, the prevalence of Schistosoma haematobium (76.1%) was similar to the baseline and the STH reduction was not significant.Longitudinal studies have reported many losses in these settings, but we were able to show that mass drug administration for control of schistosomiasis and STH present low effectiveness, that reinfections occur rapidly and that stand alone anthelmintic therapy is not a sustainable choice.
more
Neglected tropical diseases (NTDs) are targeted for global control or elimination. Recognising that the populations most in need of medicines to target NTDs are those least able to support and sustain them financially, the pharmaceutical industry created mechanisms for donating medicines and experti...se to affected countries through partnerships with the WHO, development agencies, non-governmental organisations and philanthropic donors. In the last 30 y, companies have established programmes to donate 17 different medicines to overcome the burden of NTDs. Billions of tablets, capsules, intravenous and oral solutions have been donated, along with the manufacturing, supply chains and research necessary to support these efforts. Industry engagement has stimulated other donors to support NTDs with funds and oversight so that the ‘heath benefit’ return on investment in these programmes is truly a ‘best value in public health’. Many current donations are ‘open-ended’, promising support as long as necessary to achieve defined health targets. Extraordinary global health advances have been made in filariasis, onchocerciasis, trachoma, trypanosomiasis, leishmaniasis, schistosomiasis, intestinal parasites and others; and these advances are taking place in the context of strengthening health systems and meeting the global development goals espoused by the WHO. The pharmaceutical manufacturers, already strong collaborators in initiating or supporting these disease-targeted programmes, have committed to continuing their partnership roles in striving to meet the targets of the WHO’s new NTD roadmap to 2030.
more